Generated by AI
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer. The company’s core programs are built around its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, which are designed to activate immune responses selectively in tumors while limiting effects on healthy tissue. Janux Therapeutics is advancing a pipeline of investigational candidates that target a range of cancers, including solid tumors and prostate cancer, and its research also extends to autoimmune disease applications. The company works through preclinical and early clinical development activities, supported by collaboration and discovery efforts, positioning it as a platform-driven biotechnology business centered on novel immune-oncology research.
Website10955 Vista Sorrento Parkway
San Diego, CA, 92130
United States
The latest articles about JANX.
Janux Therapeutics remains a hold, as JANX007 has a potential comeback opportunity, but declining response rates temper enthusiasm. I rate JANX stock as Hold.
2026-11-10. The following slide deck was published by Janux Therapeutics, Inc.
Summary of Jan 23's posts. Generated by AI.
Summary of Jan 22's posts. Generated by AI.
Summary of Dec 2's posts. Generated by AI.
No summary yet.
Summary of Jan 22's posts. Generated by AI.
Investors talking about JANX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.